Granted Patent
B2
US 12,703,691 · App. 17/906,653 · Granted Aug 11, 2026
PHD inhibitor compounds, compositions, and their use
Inventors:
Paul E. Fleming (Cambridge, MA); Thomas P. Blaisdell (Cambridge, MA); Senkara Rao Allu (Cambridge, MA)
Assignee:
Akebia Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.
Claims (9)
1 . A compound selected from the group consisting of:
Cmpd
No.
Structure
1
2
3
or a pharmaceutically acceptable salt thereof.
2 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Assignments (2)
SECURITY INTEREST
Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 30, 2022
From: FLEMING, PAUL E.; BLAISDELL, THOMAS P.; ALLU, SENKARA RAO
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 061267/0186 →
Continuity (2)
Provisional Application
62992616
· Mar 20, 2020
Related Publication
20230212138A1
· Jul 6, 2023
References Cited (81)
US 4663327A
· Sasse et al.
· 1987
[cited by applicant]
US 4698344A
· Sasse et al.
· 1987
[cited by applicant]
US 4772608A
· Sasse et al.
· 1988
[cited by applicant]
US 5175176A
· Sasse et al.
· 1992
[cited by applicant]
US 5620995A
· Weidmann et al.
· 1997
[cited by applicant]
US 7811595B2
· Kawamoto et al.
· 2010
[cited by applicant]
US 8323671B2
· Wu et al.
· 2012
[cited by applicant]
US 8343952B2
· Wu et al.
· 2013
[cited by applicant]
US 8524699B2
· Kai et al.
· 2013
[cited by applicant]
US 8598210B2
· Kawamoto et al.
· 2013
[cited by applicant]
US 8722895B2
· Kawamoto et al.
· 2014
[cited by applicant]
US 8940773B2
· Kawamoto et al.
· 2015
[cited by applicant]
US 9040522B2
· Brown et al.
· 2015
[cited by applicant]
US 9168249B2
· Thede et al.
· 2015
[cited by applicant]
US 9598370B2
· Kawamoto et al.
· 2017
[cited by applicant]
US 20120309977A1
· Lanthier et al.
· 2012
[cited by applicant]
US 20120322772A1
· Flamme et al.
· 2012
[cited by applicant]
US 20230159489A1
· Fleming et al.
· 2023
[cited by applicant]
US 20230227426A1
· Fleming et al.
· 2023
[cited by applicant]
CN 101213189A
· 2008
[cited by applicant]
CN 101541785A
· 2009
[cited by applicant]
CN 101600710B3
· 2009
[cited by applicant]
CN 101631785B4
· 2010
[cited by applicant]
CN 105492433B5
· 2016
[cited by applicant]
CN 106831735A
· 2017
[cited by applicant]
CN 109879804A
· 2019
[cited by applicant]
DE 3443308B6
· 1986
[cited by applicant]
DE 102006050512A1
· 2008
[cited by applicant]
DE 102007044032A1
· 2009
[cited by applicant]
EP 3336084A1
· 2018
[cited by applicant]
IN 201621021801A
· 2017
[cited by applicant]
JP S60255788B7
· 1985
[cited by applicant]
JP S61137878B8
· 1986
[cited by applicant]
JP 2008539180A
· 2008
[cited by applicant]
JP 2010507602A
· 2010
[cited by applicant]
JP 2010507605A
· 2010
[cited by applicant]
JP 2012513976A
· 2012
[cited by applicant]
JP 2016501882A
· 2016
[cited by applicant]
JP 2016515582A
· 2016
[cited by applicant]
RU 2469031C2
· 2012
[cited by applicant]
TW 200833330A
· 2008
[cited by applicant]
WO WO2006114213A1
· 2006
[cited by applicant]
WO WO2007090068A2
· 2007
[cited by applicant]
WO WO2008002576A2
· 2008
[cited by applicant]
WO WO2008040002A2
· 2008
[cited by applicant]
WO WO2008067874A1
· 2008
[cited by applicant]
WO WO2008121861A2
· 2008
[cited by applicant]
WO 2010005851A1
· 2010
[cited by applicant]
WO 2010076524A3
· 2010
[cited by applicant]
WO WO2013134660A1
· 2013
[cited by applicant]
WO WO2014089364A1
· 2014
[cited by applicant]
WO WO2014160810A1
· 2014
[cited by examiner]
WO WO2016148306A1
· 2016
[cited by applicant]
WO WO2017143131A1
· 2017
[cited by applicant]
WO WO2021188936A1
· 2021
[cited by applicant]
WO WO2021188938A1
· 2021
[cited by applicant]
WO WO2021188944A1
· 2021
[cited by applicant]
WO WO2021216530A1
· 2021
[cited by applicant]
WO WO2022036188A1
· 2022
[cited by applicant]
Tanaka (Bioorganic & Medicinal Chemistry 28 (2020) 115182, available online Nov. 9, 2019) (Year: 2019).
[cited by examiner]
International Search Report for PCT/US2021/023219 dated Jul. 6, 2021 (6 pages).
[cited by applicant]
International Search Report for PCT/US2021/023222 dated Jul. 6, 2021 (5 pages).
[cited by applicant]
International Search Report for PCT/US2021/023228 dated Jun. 28, 2021 (10 pages).
[cited by applicant]
“4-[2-(5-acetylpyridin-2-yl)-3-oxo-1H-pyrazol-4-yl]benzonitrile”, PubChem, National Center for Biotechnology Information, CID 135129723, Dec. 15, 2018 from URL: https://pubchem.ncbi.nlm.nih.gov/compound/135129723 (10 pa…
[cited by applicant]
Buchi, et al., “Synthesis and pharmacological properties of certain pyridylpyrazol-5-one”, Helvetica Chimica Acta, vol. 49 (pp. 272-280) (10 pages).
[cited by applicant]
Lee, et al., “Hypoxia signaling in human diseases and therapeutic targets”, Experimental & Molecular Medicine, vol. 51, Jun. 20, 2019, pp. 1-13, DOI: 10.1038/s12276-019-0235-1, (13 pages).
[cited by applicant]
Patani, et al. “Bioisosterism: A Rational Approach in Drug Design”, Chemical Reviews, vol. 96, No. 8, 1996, pp. 3147-3176 DOI: 10.1021/cr950066q (30 pages).
[cited by applicant]
U.S. Appl. No. 17/906,650, filed Sep. 19, 2022, Fleming et al.
[cited by applicant]
U.S. Appl. No. 17/906,652, filed Sep. 19, 2022, Fleming et al.
[cited by applicant]
U.S. Appl. No. 18/041,490, filed Feb. 13, 2023, Blaisdell et al.
[cited by applicant]
Beck et al., “Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia”, ChemMedChem, vol. 13, No. 10, Feb. 28, 2018, pp. 988-1003, DOI: 10…
[cited by applicant]
Cadieux et al., “Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)”, Bioorganic & Medicinal Chemistry Letters, vol. 22. No. 1, Nov. 25, 2011, pp. 90-95, DOI:…
[cited by applicant]
Markham, Anthony, “Vadadustat: First Approval”, Drugs, vol. 80, Aug. 27, 2020, pp. 1365-1371, DOI: 10.1007/s40265-020-01383-z, (7 pages).
[cited by applicant]
Xue et al., “Prolyl Hydroxylase-3 is down regulated in colorectal cancer cells and inhibits IKKB independent of hydroxylase activity”, Gastroenterology, vol. 138, No. 2, Feb. 2010, pp. 606-615, DOI: 10.1053/j.gastro.200…
[cited by applicant]
Compound with CAS Registry No. 5575-24-6. 2-(6-Chloro-2-pyridinyl)-1,2-dihydro-5- methyl-4-phenyl-3H-pyrazol-3-one. Nov. 16, 1984 (1 page).
[cited by applicant]
Guillo, Sandrine, et al., “N-arylation of 3-alkoxypyrazoles, the case of the pyridines”, Tetrahedron, vol. 66, No. 14, Apr. 3, 2010, pp. 2654-2663 (10 pages).
[cited by applicant]
Laskaris, Paris, et al., “A Novel Polyaminocarboxylate Compound to Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism”, Antimicrobial Agents and Chemotherapy, vol. 62, No. 6, Jun. 1, 2018 (11 pages…
[cited by applicant]